Drug-Induced Pulmonary Toxicity: Pharmacy Case #56

On its own, the chest picture is unremarkable and points nowhere in particular: ten weeks of progressive breathlessness, a dry cough, weight loss, a low-grade fever, fine bibasal crackles, desaturation on walking, and bilateral reticular shadowing. That describes a dozen conditions, and the two antibiotic courses show how it usually gets handled. What makes this case solvable is that the lungs are not the only organ involved. He has slate-grey discolouration of the face and the backs of his hands, fine deposits in both corneas noticed incidentally by an optician, and a thyroid stimulating hormone of 8.9. Nothing links a skin colour, a corneal finding and a thyroid result except a drug, and his repeat prescription has carried amiodarone 200 mg daily for eight months. Those associated findings have known frequencies that make the attribution reasonable rather than speculative: corneal microdeposits occur in at least 90% of patients on this drug though only about 10% get visual symptoms; hypothyroidism is nearly twice as prevalent as hyperthyroidism, which is why thyroid testing is advised at baseline and every six months; there is a 1% annual incidence of liver toxicity; and blue skin discolouration with photosensitivity is characteristic. The timing fits too — this toxicity generally manifests within the initial year of use, and he is eight months in. The lung findings then take their proper place. The toxicity most commonly resembles interstitial lung disease, and his physiology matches: restrictive rather than obstructive, with a transfer factor reduced out of proportion to the volume loss. It can also present as organizing pneumonia, pleural effusion, acute respiratory distress syndrome or diffuse alveolar haemorrhage, so the radiographic appearance varies and none of it is specific. That is the crux — there is no pathognomonic finding that makes this diagnosis. It is made by a comprehensive evaluation that excludes the alternatives, which is exactly what the rest of the workup does: negative blood and sputum cultures with no response to two antibiotic courses, and an echocardiogram showing an ejection fraction of 58% with normal diastolic function and valves. The single most persuasive piece of evidence is the comparison rather than any one result: there is a clear baseline chest film from when the drug was started, so the reticular change is demonstrably new. Baseline and annual chest radiographs are advised for patients on this drug precisely so that comparison exists. Two practical points close it out. Steroids have shown efficacy, and mortality from this reaction is reported at nearly 10%, so this is not a wait-and-see problem. And stopping the drug does not produce a quick answer: the half-life is several weeks and pharmacological effects can persist for one to three months after discontinuation, so neither he nor the team should read a lack of improvement over the first few weeks as evidence the diagnosis was wrong.